Tamar Tadmor
A5025358969- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Advanced Breast Cancer Therapies
- Protein Degradation and Inhibitors
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Neutropenia and Cancer Infections
- Cutaneous lymphoproliferative disorders research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Inflammatory Biomarkers in Disease Prognosis
- Neuroendocrine Tumor Research Advances
- COVID-19 and healthcare impacts
- Eosinophilic Disorders and Syndromes
Bnai Zion Medical Center
2016-2025
Technion – Israel Institute of Technology
2013-2024
Rappaport Family Institute for Research in the Medical Sciences
2016-2024
Centre for Research and Technology Hellas
2023
National and Kapodistrian University of Athens
2023
Soroka Medical Center
2023
John Wiley & Sons (United States)
2021
Hudson Institute
2021
Complejo Asistencial Universitario de Palencia
2019
Ghent University Hospital
2011
This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), rare B malignancy with high CD22 expression. The enrolled patients relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 for ≤6 cycles. Blinded independent central review determined disease response minimal residual (MRD)...
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden coexisting conditions) advanced chronic lymphocytic leukemia (CLL) have been lacking. Download PDF the Research Summary. In phase 3, open-label trial, we randomly assigned, 1:1:1:1 ratio, CLL who did not TP53 aberrations to receive six cycles chemoimmunotherapy (fludarabine–cyclophosphamide–rituximab or bendamustine–rituximab) 12 venetoclax–rituximab,...
Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine high efficacy of 95% in immunocompetent individuals, was introduced. We investigated the safety and BNT162b2 patients CLL from nine medical centers Israel, Overall 400 were included, whom 373 found be eligible for analysis antibody response. The appeared safe only grade 1-2 adverse events seen 50% patients. Following second dose, detected 43%...
Abstract Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due age, disease, and treatment-related immunosuppression. We aimed assess risk factors of outcome elucidate the impact CLL-directed treatments on course COVID-19. conducted a retrospective, international study, collectively including 941 patients CLL confirmed Data from beginning pandemic until March 16, 2021, were collected 91 centers. The case fatality rate (CFR),...
In this study we assessed the prognostic significance of absolute monocyte count and selected best cut-off value at diagnosis in a large cohort patients with diffuse B-cell lymphoma. Data were retrieved for therapy-naïve lymphoma followed Israel Italy during 1993–2010. A final 1017 was analyzed median follow up 48 months 5-year overall survival rate 68%. The level 630/mm3 counts below 71%, whereas it 59% those >630 mm3 (P=0.0002). Of patients, 521 (51%) treated chemo-immunotherapy, cohort,...
Abstract Some patients with lymphoma have monocytosis at diagnosis, but its significance is unclear. The recently recognized subpopulation, monocytic myeloid‐derived suppressor cells (M‐MDSCs), has immunoregulatory function, suppresses host anti‐tumour immunity and plays a role in cancer tolerance. Data from 91 untreated diffuse large B‐cell (DLBCL) were evaluated for >1000/mm 3 diagnosis compared number of well‐established prognostic factors DLBCL including age, stage, gender, B...
Summary Background Invasive fungal diseases (IFD) are life‐threatening infections most commonly diagnosed in acute leukaemia patients with prolonged neutropenia and uncommonly lymphoproliferative diseases. Objectives Following the initial report of aspergillosis shortly after beginning ibrutinib for chronic lymphocytic leukaemia, a survey was developed to seek additional cases IFD during treatment. Methods Local international physicians groups were approached relevant cases. Patients...
Myeloproliferative neoplasms (MPNs) are malignant disorders originating from clonal expansion of a single neoplastic stem cell and characteristically show an increase in bone marrow reticulin fibers. Lysyl oxidases (LOXs) copper‐dependent amine that play critical role the biogenesis connective tissue by crosslinking extracellular matrix proteins, collagen elastin. Expression LOX gene family members is increased associated with fibrosis. To evaluate involvement various MPNs. In‐situ...
Hypomethylating agents have become the standard therapy for patients with high‐risk myelodysplastic syndrome ( MDS ). In Israel, azacitidine AZA ) is routinely used. Yet, infectious complications are common during therapy. The current study was aimed to evaluate incidence and predisposing risk factors infections in ‐treated patients. This retrospective included treated 18 Israeli medical institutions between 2008 2011. Data on 184 [157 27 acute myeloid leukemia AML )], a median age of 71.6...